Their findings indicated that patients with metastatic CRC and KRAS mutations and co-occurring diabetes who received metformin experienced a significantly longer median survival (an additional 37.8 months) than those treated with other blood sugar-lowering drugs alongside standard systemic therapy. The gene discussed is KRAS; the disease is colorectal carcinoma.